S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opening Session Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Welcome and Introduction to Vi3C

Jan

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opening Session Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Welcome and Introduction to Vi3C

Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma

In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL

Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma

Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer

Are Food Preservatives Linked to Increased Cancer Risk